What is the FITC-Dextran Permeability Assay?

The FITC-dextran permeability assay is a widely used laboratory method for measuring how easily molecules pass through biological barriers such as the intestinal lining, blood vessel walls, or the blood-brain barrier. It works by tracking a fluorescent tracer, dextran sugar molecules tagged with fluorescein isothiocyanate (FITC), as they move across a cell layer or tissue. Wherever the tracer shows up on the “wrong” side of the barrier, or in the bloodstream after being swallowed, researchers know that barrier has become leaky. The assay’s popularity comes from its simplicity, its flexibility across different tissue types, and the fact that dextran molecules come in a range of sizes, letting scientists probe barriers at different scales of leakiness.

How the Tracer Molecule Works

Dextran is a branched sugar polymer that dissolves readily in water. On its own it is biologically inert, meaning cells do not actively absorb or break it down. By chemically attaching FITC, a bright green fluorescent dye, to the dextran chain, researchers create a molecule that glows under specific wavelengths of light and can be detected at very low concentrations with a fluorescence reader or microscope. Early work coupling FITC to dextrans showed that these tracers could be used across fluorescence microscopy and even electron microscopy, expanding their utility well beyond simple permeability testing.¹

One of the assay’s most powerful features is size selectivity. Dextrans are manufactured at specific molecular weights, commonly 4 kDa (kilodaltons), 10 kDa, 40 kDa, and 70 kDa, each corresponding to a different physical diameter. Smaller dextrans slip through gaps in a barrier more easily than larger ones. In experiments with human colon tissue, for example, a small 0.4 kDa tracer achieved about 30% transfer across the tissue over six hours, a 4 kDa FITC-dextran reached roughly 20%, and a 40 kDa dextran managed only about 12%.² By running multiple sizes simultaneously, researchers can figure out not just whether a barrier is leaky but how large the openings have become.

This size dependency also plays a critical role in blood-brain barrier studies. Smaller FITC-dextrans always leak out of damaged vessels more readily than larger ones, but the smaller tracers are also more water-soluble and can wash out during tissue preparation. Freezing brain tissue quickly after the experiment, rather than soaking it in chemical fixatives, preserves the signal from low molecular weight tracers and gives a more accurate picture of the leak.³

The In Vitro Transwell Setup

The most common way to run a FITC-dextran permeability assay in the lab is with a Transwell system. Picture a small plastic insert with a porous membrane at its bottom, sitting inside a well of a culture plate. Cells, typically intestinal epithelial lines like Caco-2 or endothelial cells for blood vessel studies, are grown on top of that membrane until they form a continuous single-cell layer. The upper chamber (apical side) represents the inside of the gut or the blood vessel lumen, while the lower chamber (basolateral side) represents the tissue or blood on the other side.⁴

Once the cells are ready, FITC-dextran dissolved in culture medium is added to the apical chamber. After a set incubation period, usually a few hours, samples are collected from the basolateral chamber and their fluorescence is measured. More fluorescence in the lower chamber means more tracer crossed the barrier, which means the barrier is more permeable. In one study using human umbilical vein endothelial cells, treating the monolayer with a dipeptide called AlaGln tightened the barrier so that the amount of 10 kDa FITC-dextran reaching the basolateral side dropped to about 32% of what untreated cells allowed through.⁵ That kind of clear, quantifiable difference is exactly why the assay is so useful for testing drugs or conditions that might strengthen or weaken barriers.

Most labs pair FITC-dextran permeability with a second measurement called transepithelial electrical resistance, or TEER. TEER measures how much electrical current can pass through the cell layer, giving a quick snapshot of how tightly the cells are joined together. FITC-dextran flux and TEER complement each other because they capture different aspects of barrier function: TEER is sensitive to the movement of small ions, while the dextran assay tracks the passage of larger molecules.⁴

In Vivo Gut Permeability Testing

The FITC-dextran assay is not limited to cells growing in a dish. A common in vivo protocol involves giving mice FITC-dextran by oral gavage, essentially delivering it straight into the stomach through a feeding needle. The animals are fasted beforehand to empty the gut. After a waiting period, typically around four hours, blood is drawn and the plasma fluorescence is measured. Higher fluorescence in the blood means more of the tracer leaked through the intestinal wall and entered the circulation.⁶

This approach is a staple in animal models of inflammatory bowel disease, infection, and other conditions that damage the gut lining. Increased intestinal permeability is a hallmark of these diseases, and the FITC-dextran gavage method provides a straightforward biomarker of disease severity.⁷ In some protocols, researchers also image the animals while still alive using a fluorescence imaging chamber. Residual fluorescence in the abdominal cavity or hepatic uptake of the probe indicates that the tracer has migrated through the portal system, giving spatial information about where the leak is happening.⁶

Blood-Brain Barrier Applications

The blood-brain barrier is one of the tightest biological barriers in the body, and measuring its breakdown is critical in stroke, traumatic brain injury, and neuroinflammation research. FITC-dextran is widely used here, often by perfusing or injecting the tracer into the bloodstream and then examining brain tissue for signs of extravasation, meaning the tracer has leaked out of blood vessels into the surrounding brain tissue.⁸

In stroke models, the spatial pattern of FITC-dextran leakage reveals how the blood-brain barrier breaks down over time. One study in rats showed that as the duration of ischemia (blocked blood flow) increased, high molecular weight FITC-dextran progressively invaded the brain in a characteristic pattern: first appearing in the medial striatum, spreading laterally, and finally reaching the cortex. The distribution of severe vascular disruption correlated strongly with markers of tissue death, and ultrastructural examination of leaky regions showed swollen cellular structures consistent with serious damage.⁹ FITC-dextran extravasation from the brain vessels increased significantly between two and eight hours of occlusion, providing a timeline of barrier deterioration that helps researchers identify therapeutic windows.⁹

FITC-dextran has also been used alongside focused ultrasound techniques that deliberately open the blood-brain barrier to deliver drugs. Researchers can then image the extravasation of different-sized fluorescent molecules at single blood vessel resolution to understand exactly how much and where the barrier was opened.¹⁰ In neuroinflammation research, knocking out a gene called CLEC14A in mice increased FITC-dextran permeability and decreased electrical resistance across endothelial cells, demonstrating that this gene plays a protective role in maintaining barrier integrity.¹¹

Some protocols combine FITC-dextran with Evans blue dye, another classic permeability tracer that binds to albumin in the blood. In one approach, Evans blue circulates for 30 minutes to mark areas of leakage, and then FITC-dextran is injected for just two minutes to outline vascular contours. Dividing the Evans blue signal by the vascular area traced by FITC-dextran gives a normalized measure of leakage that accounts for differences in blood vessel density between brain regions.¹²

Ex Vivo Testing with Ussing Chambers

A third way to use FITC-dextran is in an ex vivo system called the Ussing chamber. Here, a piece of actual tissue, often a biopsy from the intestine, is mounted between two halves of a small chamber. Fluid bathes both sides of the tissue, and FITC-dextran is added to one side. Over time, the amount of tracer appearing on the other side is measured to calculate permeability. This approach is particularly valuable for studying human tissue directly, including biopsies from patients with celiac disease or inflammatory bowel disease.¹³

In a mouse model of colitis, Ussing chamber analysis of colon tissue showed both reduced electrical resistance and increased flux of 4 kDa FITC-dextran, confirming that the disease had made the barrier leakier. Healthy tissue, by contrast, showed virtually no passage of the tracer, demonstrating intact mucosal integrity.¹⁴

What the Assay Cannot Tell You on Its Own

A common misconception is that FITC-dextran permeability directly reflects the state of tight junctions, the protein complexes that seal neighboring cells together. In reality, the tracer can cross a barrier by more than one route. The paracellular route, squeezing between cells through or around tight junctions, is what most researchers are interested in. But molecules can also cross via transcytosis, where the cell actively engulfs material on one side and releases it on the other. An increase in FITC-dextran passage could reflect loosened tight junctions, increased transcytosis, or both.¹⁵

This matters because different diseases and experimental conditions may affect the two routes differently. In diabetic mice, for instance, one study found that intestinal paracellular permeability actually decreased while transcellular permeability was unaffected, a result that would look confusing if you assumed all FITC-dextran movement was paracellular.¹⁵ Distinguishing the two routes usually requires running additional experiments, such as using tracers known to move primarily by transcytosis, or pairing the dextran assay with TEER measurements and tight junction imaging.

Getting Reliable Results

The FITC-dextran assay looks simple on paper, but small procedural differences can dramatically affect the numbers. In broiler chicken research, where the assay is used to study gut health, one optimization study found that increasing the gavage dose, shortening the blood collection window from two and a half hours to one hour, using non-FITC-dextran serum instead of PBS as the blank, and adjusting the fluorescence reader’s sensitivity settings all produced more consistent and reliable results.¹⁶ Fasting duration, sample handling temperature, and the specifics of standard curve preparation all influence the final measurement.¹⁷

The choice of platform also introduces variability. Microfluidic organ-on-chip devices, which allow cells to experience fluid flow and shear stress more like they would in the body, sometimes give different permeability readings than static Transwell systems. Shear stress has been shown to enhance paracellular transport of intermediate-sized molecules like dextran in microfluidic devices compared to Transwells.¹⁸ This does not necessarily mean one platform is “wrong,” but it does mean results are not always directly comparable across different experimental setups.

Real-Time Imaging with Two-Photon Microscopy

Beyond endpoint measurements where you check how much tracer crossed a barrier after a set time, FITC-dextran can be watched in real time using intravital two-photon microscopy. This advanced imaging technique allows researchers to observe dextran leaking out of blood vessels in a living animal, capturing the dynamic process of barrier breakdown as it happens rather than just the end result. Different sizes of fluorescence-labeled dextran can be injected simultaneously to visualize how leaky vessels are at different molecular scales during inflammation or other challenges.¹⁹

This real-time approach adds a dimension that static assays miss. A Transwell experiment tells you the cumulative amount of tracer that crossed over four hours, but intravital imaging reveals the kinetics: whether the leak is sudden or gradual, whether it is localized to a few vessels or widespread, and how quickly the barrier reseals after the initial insult. For studying acute events like the first minutes after a stroke or an allergic reaction, that temporal resolution is invaluable.

Photobleaching and Alternative Fluorophores

FITC has one well-known weakness: it photobleaches relatively quickly, meaning its fluorescence fades with prolonged light exposure. Compared to newer dyes like Alexa Fluor 568, FITC loses its brightness significantly earlier during continuous imaging, and the difference in photostability is statistically significant.²⁰ For a standard plate-reader measurement where each sample gets a single brief read, this is not a major issue. But for microscopy work where samples are imaged repeatedly or for extended periods, photobleaching can cause researchers to underestimate the actual amount of tracer present.

Alternative fluorescent conjugates address this problem. Rhodamine-labeled dextrans (like TRITC-dextran) and dextrans conjugated to Alexa Fluor dyes offer better photostability and emit at different wavelengths, which also makes it possible to run multi-tracer experiments. A study using human colon tissue, for instance, combined Lucifer Yellow (0.4 kDa), FITC-dextran (4 kDa), and TRITC-dextran (40 kDa) in a single experiment to simultaneously measure permeability at three different molecular sizes.² Each tracer fluoresces at a distinct wavelength, so the signals do not overlap. Despite these alternatives, FITC-dextran remains the default choice in most labs because it is inexpensive, widely available, well-characterized across decades of literature, and performs reliably in the short-duration, single-read experiments that make up the bulk of permeability work.